Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EFFEXOR XR

« Back to Dashboard
Effexor Xr is a drug marketed by Wyeth Pharms Inc and is included in one NDA. It is available from seventeen suppliers. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are sixty-five drug master file entries for this compound. Nineteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

Summary for Tradename: EFFEXOR XR

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list97

Clinical Trials for: EFFEXOR XR

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study
Status: Completed Condition: Healthy

Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
Status: Withdrawn Condition: Major Depressive Disorder

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
Status: Completed Condition: Bariatric Surgery; Gastric Bypass; Roux-en-Y Gastric Bypass

Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions
Status: Completed Condition: Healthy

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions
Status: Completed Condition: Healthy

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects
Status: Active, not recruiting Condition: Healthy Subjects

Venlafaxine PK Following Bariatric Surgery
Status: Active, not recruiting Condition: Roux en Y Gastric Bypass; Sleeve Gastrectomy

Study Evaluating Effexor XR for Major Depression.
Status: Completed Condition: Depression

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997RXNo6,419,958*PED<disabled>Y<disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997DISCNNo6,419,958*PED<disabled>Y<disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997RXNo6,419,958*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EFFEXOR XR

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 19975,916,923*PED<disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 19974,535,186*PED<disabled>
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 19975,916,923*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EFFEXOR XR

Drugname Dosage Strength RLD Submissiondate
venlafaxine hydrochlorideExtended-release Tablets37.5 mg, 75 mg and 150 mgEffexor XR5/3/2007
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc